Also found in: Acronyms.
References in periodicals archive ?
Localization of fibroblast growth factor 2 (FGF-2) protein and the receptors FGFR 1-4 in normal human seminiferous epithelium.
First, ProChon retains rights to develop the antibodies against FGFR 3 in all non-cancer indications.
Genetic heterogeneity of Saethre-Chotzen syndrome, due to TWIST and FGFR mutations.
Lenvatinib exhibits rapid and potent inhibition of kinase activity1, simultaneously inhibiting the activity of VEGFR, FGFR and also RET which are especially involved in tumor angiogenesis and proliferation of thyroid cancer, and has been confirmed to possess a novel binding mode (Type V)1.
In dominant diseases, such as FGFR mutations that cause craniosynostosis syndromes, the sequence difference between the two alleles in the heteroduplex causes a physical bulge at the site of the sequence mismatch, which produces a localized lowering of the melting temperature.
This potentially makes lenvatinib a first-in-class treatment, especially given that it simultaneously inhibits the kinase activities of FGFR as well as VEGFR.
A Phase I study of BGJ398 provides the first clinical evidence of activity against cancers that are driven by dysregulation of the FGFR pathway.
Lenvatinib simultaneously inhibits VEGFR, FGFR and also RET which are especially involved in tumour angiogenesis and proliferation of thyroid cancer.
Formulation switch and pharmacokinetics/pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor, in a first-in- human dose escalation trial in solid tumors patients
Biopharmaceuticals company Debiopharm Group has announced commencement of Phase I trial of Debio 1347 (CH5183284) in advanced solid tumors with FGFR Alterations.
The Cancer Discovery publication outlines the unique discovery process led by Blueprint Medicines' scientists to craft selective, covalent drugs to FGFR4, which historically had been a challenging kinase for drug discovery due to the sequence similarities with the other FGFR paralogs.